On Friday, Shares of Pfizer Inc. (NYSE:PFE), lost -1.63% to $31.37.
Pfizer declared that it has accomplished its acquisition of Hospira, Inc.
“We are happy that Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, is now part of Pfizer. We want to welcome our new Hospira colleagues to Pfizer. We are excited to add their talents and proud of the shared commitment of all Pfizer colleagues to serving patients worldwide,” said Ian Read, chairman and chief executive officer, Pfizer. “We believe that through this transaction, we’ve created value for our shareholders by delivering incremental revenue and predictable EPS growth in the near-term by strengthening our GEP business and positioning it for future growth.”
Pfizer’s GEP business now has a leadership position in the large and growing sterile injectables category, with a robust portfolio of both generic and branded products. The global market for generic sterile injectables is estimated to be $70 billion in 2020. In addition, GEP has significantly advanced its biosimilars business with a broadened portfolio of marketed products and pipeline assets, which will benefit from Pfizer’s best-in-class capabilities in monoclonal antibody development and manufacturing. The global market for biosimilars is estimated to be about $20 billion in 2020. The industry-leading medication administration systems business, which is now part of GEP, is a complementary business that benefits patients and healthcare systems through improved accuracy and productivity in clinical care. Pfizer is now poised to use its commercial capabilities, global scale, scientific expertise, and manufacturing prowess, which now comprises two of the largest sterile injectable manufacturing facilities in the world, to maximize the global potential of its improved GEP portfolio of sterile injectables, biosimilars and medication administration systems.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Finally, Infoblox Inc. (NYSE:BLOX), ended its last trade with -8% loss, and closed at $18.28.
Infoblox stated its financial results for its fourth fiscal quarter and fiscal year ended July 31, 2015. Total net revenue for the fourth quarter of fiscal 2015 was a record $87.0 million, an improvement of 34.0% on a year-over-year basis. Total net revenue for fiscal 2015 was a record $306.1 million, an improvement of 22.3% contrast with the total net revenue of $250.3 million in fiscal 2014.
On a GAAP basis, the Company stated a net loss of $4.7 million, or $0.08 net loss per fully diluted share, for the fourth quarter of fiscal 2015, contrast with a net loss of $9.5 million, or $0.17 net loss per fully diluted share, for the fourth quarter of fiscal 2014. For fiscal 2015, the Company stated a GAAP basis net loss of $27.1 million, or $0.48 net loss per fully diluted share, contrast with a net loss of $23.9 million, or $0.45 net loss per fully diluted share, in fiscal 2014.
The Company stated non-GAAP net income of $7.3 million, or $0.12 diluted net income per share on a non-GAAP weighted-average share basis, for the fourth quarter of fiscal 2015, contrast with non-GAAP net income of $1.9 million, or $0.03 diluted net income per share on a non-GAAP weighted-average share basis, for the fourth quarter of fiscal 2014. For fiscal 2015, on a non-GAAP basis, the Company stated net income of $22.7 million, or $0.38 diluted income per share contrast with net income of $19.5 million, or $0.34 diluted income per share, in fiscal 2014.
Infoblox Inc. develops, markets, and sells automated network control solutions worldwide. Its appliance-based solution combines real-time IP address administration with the automation of network control, and network change and configuration administration processes in physical and virtual appliances.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
